The U.S. Food and Drug Administration has approved the supplemental new drug application for Trelegy Ellipta for the maintenance treatment of asthma in patients ages 18 years and older. This new indication is important because its ingredients have dental implications and adverse effects that may be additive and synergistic. Tom Viola, RPh, explains more in this article.
Read more on DrBicuspid.com
The U.S. Food and Drug Administration has approved the supplemental new drug application for Trelegy Ellipta for the maintenance treatment of asthma in patients ages 18 years and older. This new indication is important because its ingredients have dental implications and adverse effects that may be additive and synergistic. Tom Viola, RPh, explains more in this article.
No comments:
Post a Comment